GSK•benzinga•
The China National Medical Products Administration Has Accepted For Review GSK's New Drug Application For Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Patients With Chronic Obstructive Pulmonary Disease With An Eosinophilic Phenotype
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga